Related Experiment Video
Updated: Sep 9, 2025
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Simvastatin-Mediated Molecular Mechanisms Underlying the Growth Inhibition of Testicular Leydig Tumour Cells
Arianna De Luca1, Lucia Zavaglia1, Lucia Francesca Vuono1
1Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, Rende, Cosenza, Italy.
Abstract:
Leydig cell tumours (LCTs) are uncommon stromal neoplasms of the testis, accounting for less than 3% of all gonadal cancers. Most of them are benign, but the malignant ones are very aggressive without specific effective treatment. Several studies reported pharmacologic insight into the use of statins as anti-tumour agents, but their efficacy on LCTs has not been investigated. Previously, we emphasised the central role of insulin-like growth factor 1 (IGF1)/insulin-like growth factor 1 receptor (IGF1R) signalling in Leydig cell tumorigenesis; here, we showed that simvastatin reduces cell proliferation, determines cell cycle arrest at the G1 phase, and induces reactive oxygen species (ROS) accumulation and apoptosis in R2C and LC540 rat Leydig tumour cells. Furthermore, it prevents isoprenoid farnesyl pyrophosphate (FPP) formation and decreases IGF1R expression, leading to the breakdown of the IGF1R signalling pathway. Importantly, we observed that simvastatin synergised with cisplatin in reducing tumour cell proliferation. Collectively, these data suggest that simvastatin is a potential anticancer drug capable of counteracting LCT growth, and it could be proposed as an adjuvant for chemotherapy in LCT treatment.
Insights
Simvastatin, a cholesterol-lowering drug, effectively inhibits Leydig cell tumour (LCT) growth by disrupting key signalling pathways. It shows potential as an adjuvant therapy to improve chemotherapy outcomes for LCT patients.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Leydig cell tumours (LCTs) are rare testicular cancers, with malignant forms lacking effective treatments.
- The insulin-like growth factor 1 (IGF1)/IGF1 receptor (IGF1R) pathway is crucial in LCT development.
- Statins' anti-tumour potential is recognized, but their effect on LCTs remains unexplored.
Purpose of the Study:
- To investigate the efficacy of simvastatin, a statin, against Leydig cell tumours.
- To elucidate the molecular mechanisms underlying simvastatin's action on LCT cells.
- To evaluate simvastatin's potential as an adjuvant therapy in combination with chemotherapy.
Main Methods:
- Utilized R2C and LC540 rat Leydig tumour cell lines.
- Assessed simvastatin's effects on cell proliferation, cell cycle, apoptosis, and reactive oxygen species (ROS) production.
- Investigated simvastatin's impact on isoprenoid farnesyl pyrophosphate (FPP) formation and IGF1R signalling.
- Examined the synergistic effect of simvastatin with cisplatin.
Main Results:
- Simvastatin significantly reduced LCT cell proliferation and induced G1 phase cell cycle arrest.
- Simvastatin treatment led to increased ROS accumulation and apoptosis in LCT cells.
- Simvastatin inhibited FPP formation and decreased IGF1R expression, disrupting the IGF1R signalling pathway.
- Simvastatin demonstrated a synergistic effect with cisplatin in inhibiting tumour cell proliferation.
Conclusions:
- Simvastatin exhibits potent anti-cancer properties against Leydig cell tumours.
- The drug functions by inhibiting cell proliferation, inducing apoptosis, and disrupting IGF1R signalling.
- Simvastatin holds promise as a potential adjuvant therapeutic agent for LCT treatment, enhancing chemotherapy efficacy.
More Related Videos
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
09:41Functional Assessment of Kinesin-7 CENP-E in Spermatocytes Using In Vivo Inhibition, Immunofluorescence and Flow Cytometry
Published on: December 28, 2021
